Jun 2026 (Q2 FY26) — Aug 12, 2026
Liquidia Corporation Q2 FY26 — YUTREPIA Drives Strong Revenue Growth and Profitability
Read the full callLiquidia (LQDA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Liquidia earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 172 | +1842.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 49.8 | +474.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 74.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$34.13 −0.64% · −$0.22
Performance +51.8% 1Y
1Y: $22.48 on 17 Oct 2025 → $34.13. High $91.03 (10 Aug 2026), low $22.02 (23 Oct 2025).
- Previous close
- $34.35
- 52-week range
- $22.02 – $91.03
- One year
- +39.65%
Overview
- Symbol
- LQDA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 11, 2026
Liquidia Corporation Q1 FY26 — YUTREPIA Drives Strong Growth and Profitability
Read the full callDec 2025 (FY25) — Mar 5, 2026
Liquidia Corporation FY25 — YUTREPIA Drives Strong Launch Momentum and Profitability
Read the full callEvery analysed call
Liquidia earnings calls (LQDA)
Financials
What the filings say
Net profit, year on year: +280% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 3 | 3 | 9 | 54 | 92 | 133 | 172 |
| Expenses | 34 | 39 | 39 | 46 | 53 | 72 | 71 | 86 |
| Operating profit | -29 | -36 | -35 | -38 | 2 | 20 | 62 | 86 |
| Operating margin | −656.2% | −1237.8% | −1135.4% | −424.4% | 3.3% | 21.5% | 46.3% | 49.8% |
| Other income | -2 | -2 | -3 | -4 | -5 | -5 | -5 | -4 |
| Interest | 4 | 2 | 5 | 6 | 7 | 7 | 6 | 6 |
| Profit before tax | — | — | -38 | -42 | — | — | 57 | 82 |
| Tax rate | — | — | 0.0% | 0.0% | — | — | 6.9% | 8.5% |
| Net profit | -31 | -38 | -38 | -42 | -4 | 15 | 53 | 75 |
| EPS ($ per share) | -0.40 | — | -0.45 | -0.49 | -0.04 | — | 0.60 | 0.84 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -215 | -275 | -310 | -351 | -429 | -557 | -626 |
| Total liabilities | 34 | 28 | 28 | 39 | 71 | 151 | 283 |
| Fixed assets | 9 | 7 | 5 | 4 | 4 | 8 | 12 |
| Total assets | 69 | 100 | 94 | 129 | 118 | 230 | 328 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -48 | -54 | -34 | -29 | -42 | -93 | -36 |
| Cash from investing | -2 | 0 | -0 | -1 | -11 | -8 | -6 |
| Cash from financing | 66 | 63 | 26 | 65 | 43 | 195 | 60 |
| Net cash flow | 16 | 10 | -8 | 36 | -10 | 93 | 18 |
| Capital expenditure | -2 | -1 | -0 | -1 | -1 | -5 | -4 |
| Free cash flow | -50 | -55 | -34 | -29 | -43 | -98 | -40 |
LQDA revenue by segment
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Single Reportable | 100% | 100% | 100% | 100% | 100% | 100% | +1842.7% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
290 filings between Oct 27, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
$317.9K
1 purchase by 1 insider
Sales
$230.58M
174 sales by 15 insiders
59% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 96
- Option exercise — converted options into shares
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Bloch Stephen M | — | $125.05M | Oct 5, 2026 |
| JEFFS ROGER | — | $32.18M | Oct 12, 2026 |
| Kaseta Michael | — | $16.24M | Oct 12, 2026 |
| Manning Paul B | — | $12.78M | Jun 4, 2026 |
| Saggar Rajeev | — | $11.30M | Oct 12, 2026 |
| Adair Jason | — | $7.89M | Oct 12, 2026 |
| Moomaw Scott | — | $5.66M | Oct 12, 2026 |
| Rielly-Gauvin Katherine | — | $4.09M | Aug 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Saggar Rajeev Chief Medical Officer | Sale 10b5-1 plan | 9,218 | $262.5K |
| Oct 12, 2026 | Kaseta Michael CFO and COO | Sale 10b5-1 plan | 18,938 | $539.4K |
| Oct 12, 2026 | Schundler Russell General Counsel | Sale 10b5-1 plan | 13,692 | $389.9K |
| Oct 12, 2026 | Moomaw Scott Chief Commercial Officer | Sale 10b5-1 plan | 8,863 | $252.4K |
| Oct 12, 2026 | Krepp Sarah Chief Human Resource Officer | Sale 10b5-1 plan | 5,245 | $149.4K |
| Oct 12, 2026 | JEFFS ROGER Chief Executive Officer | Sale 10b5-1 plan | 32,744 | $932.5K |
| Oct 12, 2026 | Adair Jason Chief Business Officer | Sale 10b5-1 plan | 7,301 | $207.9K |
| Oct 12, 2026 | Boyle Dana Chief Accounting Officer | Sale 10b5-1 plan | 5,892 | $167.8K |
| Oct 12, 2026 | Khindri Sanjeev Chief Development Officer | Sale 10b5-1 plan | 1,101 | $31.4K |
| Oct 9, 2026 | Schundler Russell General Counsel | Option exercise 10b5-1 plan | 6,409 | — |
| Oct 9, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 3,906 | — |
| Oct 9, 2026 | Boyle Dana Chief Accounting Officer | Option exercise 10b5-1 plan | 3,178 | — |
| Oct 9, 2026 | Moomaw Scott Chief Commercial Officer | Option exercise 10b5-1 plan | 3,108 | — |
| Oct 9, 2026 | Krepp Sarah Chief Human Resource Officer | Option exercise 10b5-1 plan | 3,178 | — |
| Oct 9, 2026 | Schundler Russell General Counsel | Option exercise 10b5-1 plan | 3,758 | — |
| Oct 9, 2026 | Kaseta Michael CFO and COO | Option exercise 10b5-1 plan | 5,828 | — |
| Oct 9, 2026 | Saggar Rajeev Chief Medical Officer | Option exercise 10b5-1 plan | 3,530 | — |
| Oct 9, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 2,474 | — |
| Oct 9, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 3,868 | — |
| Oct 9, 2026 | Saggar Rajeev Chief Medical Officer | Option exercise 10b5-1 plan | 4,486 | — |
| Oct 9, 2026 | JEFFS ROGER Chief Executive Officer | Option exercise 10b5-1 plan | 13,833 | — |
| Oct 9, 2026 | JEFFS ROGER Chief Executive Officer | Option exercise 10b5-1 plan | 14,333 | — |
| Oct 9, 2026 | Kaseta Michael CFO and COO | Option exercise 10b5-1 plan | 7,049 | — |
| Oct 9, 2026 | Moomaw Scott Chief Commercial Officer | Option exercise 10b5-1 plan | 4,358 | — |
| Oct 5, 2026 | Bloch Stephen M Director | Sale | 235,477 | $6.39M |
| Sep 14, 2026 | SINGH RAMAN Director | Option exercise | 8,468 | $78.8K |
| Sep 14, 2026 | SINGH RAMAN Director | Sale | 8,468 | $560.2K |
| Sep 11, 2026 | SINGH RAMAN Director | Sale | 9,024 | $619.2K |
| Sep 11, 2026 | SINGH RAMAN Director | Option exercise | 556 | $4.8K |
| Sep 11, 2026 | SINGH RAMAN Director | Option exercise | 8,468 | $78.8K |
| Sep 1, 2026 | Krepp Sarah Chief Human Resource Officer | Sale 10b5-1 plan | 274 | $18.6K |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 10,762 | $152.8K |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 9,000 | $83.8K |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Sale 10b5-1 plan | 41,832 | $2.89M |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Sale 10b5-1 plan | 31,799 | $2.20M |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 11,799 | $109.8K |
| Aug 21, 2026 | Adair Jason Chief Business Officer | Option exercise 10b5-1 plan | 238 | $3.4K |
| Aug 20, 2026 | Rielly-Gauvin Katherine Director | Sale 10b5-1 plan | 18,393 | $1.33M |
| Aug 20, 2026 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 plan | 6,666 | $17.3K |
| Aug 20, 2026 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 plan | 11,727 | $29.4K |
| Aug 19, 2026 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 plan | 23,455 | $58.9K |
| Aug 19, 2026 | Rielly-Gauvin Katherine Director | Sale 10b5-1 plan | 36,789 | $2.76M |
| Aug 19, 2026 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 plan | 13,334 | $34.5K |
| Aug 19, 2026 | Saggar Rajeev Chief Medical Officer | Sale | 50,000 | $3.70M |
| Aug 19, 2026 | Saggar Rajeev Chief Medical Officer | Option exercise | 50,000 | $186.5K |
| Aug 17, 2026 | Saggar Rajeev Chief Medical Officer | Sale | 29,534 | $2.27M |
| Jul 27, 2026 | Boyle Dana Chief Accounting Officer | Sale 10b5-1 plan | 1,600 | $140.0K |
| Jul 27, 2026 | Adair Jason Chief Business Officer | Sale 10b5-1 plan | 688 | $60.2K |
| Jul 23, 2026 | Bloch Stephen M Director | Sale | 3,600 | $326.5K |
| Jul 23, 2026 | Bloch Stephen M Director | Sale | 96,400 | $8.62M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Liquidia Corp
Free account. Everything above stays public.
Write why you follow Liquidia Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading